Skip to main content
Monday, November 16, 2026Nov 16

Valeant CEO to tell Congress he regrets drug price hikes

FILE - In this Tuesday, May 19, 2015, file photo, Valeant Pharmaceuticals CEO J. Michael Pearson poses at the company's annual general meeting in Montreal. Senators investigating price hikes by Valeant Pharmaceuticals will question hedge fund manager William Ackman and former finance chief Robert Schiller at a hearing scheduled for Wednesday, April 27, 2016.  (Ryan Remiorz/The Canadian Press via AP, File) MANDATORY CREDIT
FILE - In this Tuesday, May 19, 2015, file photo, Valeant Pharmaceuticals CEO J. Michael Pearson poses at the company's annual general meeting in Montreal. Senators investigating price hikes by Valeant Pharmaceuticals will question hedge fund manager William Ackman and former finance chief Robert Schiller at a hearing scheduled for Wednesday, April 27, 2016. (Ryan Remiorz/The Canadian Press via AP, File) MANDATORY CREDIT

WASHINGTON (AP) – The outgoing CEO of embattled drugmaker Valeant Pharmaceuticals will tell lawmakers Wednesday that he was “too aggressive” and regrets drastically hiking prices for several critical medicines, according to testimony provided to The Associated Press.

J. Michael Pearson will issue the unusual mea culpa on Capitol Hill for the business strategy that made Valeant an industry powerhouse but also triggered a vigorous backlash against the Canadian drugmaker.

“Let me state plainly that it was a mistake to pursue, and in hindsight I regret pursuing, transactions where a central premise was a planned increase in the prices of the medicines,” Pearson states in the written testimony.

The comments come days before Pearson is to be replaced as Valeant CEO, and may not win much sympathy from members of the Senate Committee on Aging. The committee is investigating the dramatic price increases pushed by Valeant and several other drugmakers.

Valeant announced Monday that it would replace Pearson as CEO early next month with Joseph Papa, the current CEO of Perrigo Co.